Zhonghua Nei Ke Za Zhi. 2023 Aug 1;62(8):902-930. doi: 10.3760/cma.j.cn112138-20221013-00755.
Chronic kidney disease (CKD) has become a serious public health concern that endangers human health on a global scale. In China, the prevalence of CKD in adults is 10.8%; however, public awareness and the diagnostic rates of CKD in the Chinese population are relatively low. Moreover, China has not yet established a national CKD screening system or developed standardized diagnostic protocols and treatment pathways. Therefore, there is an urgent need to strengthen the prevention and control of CKD and promote the management of this disease. These guidelines were initiated by the Chinese Preventive Medicine Association for Kidney Disease. The quality of evidence and guideline recommendation were determined by applying the Oxford Centre for Evidence-Based Medicine (CEBM) System. These new guidelines describe 38 recommendations that aim to standardize the early screening, management, diagnosis and treatment of CKD, thus promoting the integrated prevention and control of kidney disease in China.
慢性肾脏病(CKD)已成为一个严重的公共卫生问题,在全球范围内危害人类健康。在中国,成人CKD患病率为10.8%;然而,中国人群对CKD的知晓率和诊断率相对较低。此外,中国尚未建立全国性的CKD筛查系统,也未制定标准化的诊断方案和治疗路径。因此,迫切需要加强CKD的预防和控制,并推动该疾病的管理。这些指南由中国预防医学会肾脏病学分会发起。证据质量和指南推荐通过应用牛津循证医学中心(CEBM)系统来确定。这些新指南描述了38条建议,旨在规范CKD的早期筛查、管理、诊断和治疗,从而推动中国肾脏病的综合防治。